Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efzilonkofusp alfa - GI Innovation

Next Previous
Drug Profile

Efzilonkofusp alfa - GI Innovation

Alternative Names: GI-102

Latest Information Update: 02 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GI Innovation
  • Developer GI Innovation; GI Longevity
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Apoptosis inhibitors; Cell death stimulants; Cytotoxic T-lymphocyte antigen 4 inhibitors; Interleukin 2 replacements; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Unspecified
  • Phase I/II Solid tumours

Most Recent Events

  • 26 Jan 2026 Phase-II clinical trials in Unspecified indication (In volunteers) in Australia (IV) (NCT07363057)
  • 29 Dec 2025 Mayo Clinic plans a phase II trial for Glioblastoma and Astrocytoma (Combination therapy, Monotherapy, Recurrent, Late-stage disease, Neo-adjuvant therapy) in USA (IV), in December 2025 (NCT07301268)
  • 06 Dec 2025 GI Innovation plans phase IIa CARNATION trial Diffuse-large-B-cell-lymphoma (second-line or greater therapy) (IV) (KCT0009580)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top